Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 11 of 11 entries
View as:

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

Phase: N/A Priority: Normal
NCT ID: NCT07014215 Org: User:
Start: 06/30/25 End: 05/31/29 Due: 05/31/30

Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06714708 Org: User:
Start: 11/20/24 End: 06/01/27 Due: 06/01/28

Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04609891 Org: User:
Start: 05/26/20 End: 05/16/21 Due: 05/16/22

A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05414630 Org: User:
Start: 06/30/22 End: 06/30/25 Due: 06/30/26

Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06395844 Org: User:
Start: 05/01/24 End: 12/31/26 Due: 12/31/27

Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT06973343 Org: User:
Start: 05/31/25 End: 12/31/27 Due: 12/31/28

Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06973330 Org: User:
Start: 07/31/25 End: 05/01/27 Due: 05/01/28

Tislelizumab Combined with Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Phase: N/A Priority: Normal
NCT ID: NCT06838208 Org: User:
Start: 02/25/25 End: 04/01/28 Due: 04/01/29

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06437353 Org: User:
Start: 05/25/24 End: 10/30/27 Due: 10/30/28

An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06468254 Org: User:
Start: 06/30/24 End: 03/30/26 Due: 03/30/27

METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06884345 Org: User:
Start: 03/13/25 End: 12/31/28 Due: 12/31/29